MarketInOut Stock Screener Log In | Sign Up
 

Keros Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Keros Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization221.07 mln
Float18.15 mln
Earnings Date11/11/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-4.19
Highly reliable

Relative Strength

34 / 100
Underperforming

Debt / Equity

0.06
Debt-free

Pre-Tax Margin

-573%
Severely loss-making

ROE

-18.39
Negative

Business Description

Keros Therapeutics is a US-based drug development company focused on treating diseases caused by faulty protein signaling in the body. Its two lead drugs, rinvatercept and elritercept, are currently being tested in clinical trials for serious conditions including muscular dystrophy, ALS, and certain blood disorders. The company works alongside partners Hansoh Healthtech and Takeda Pharmaceuticals to bring these treatments to market. Founded in 2015 and based in Lexington, Massachusetts, Keros continues to build its pipeline with the goal of addressing significant unmet medical needs.

Key Fundamentals

EPS-3.27
ROE-18.39
RPS0.56
ROIC-248
ROA-17.02
EBITDA, mln-84.50
EV / EBITDA0.19
EV / EBIT0.19
Revenue, mln15.01

Quote Details

Last 11.28
Change -0.07 (-0.62%)
Open 11.28
Volume 120,901
Turnover 1,363,763
Average Volume 169,897

Financial Ratios

Pre-Tax Profit Margin-573
Leverage Ratio1.10
Current Ratio21.96
Price / Book0.86
Price / Tangible Book0.86
Debt / Equity0.06
Price / Sales29.69

Financial Strength

Altman Z-Score2.79
Piotroski F-Score 3 / 9
Beneish M-Score-4.19
Short Ratio6.41
Short % of Float6.67

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 5.82% 90 / 100   
1 Month -2.34% 49 / 100   
2 Months 6.31% 84 / 100   
6 Months -2% 48 / 100   
1 Year -27.51% 27 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog